MCID: MCR004
MIFTS: 54

Macroglobulinemia

Categories: Metabolic diseases

Aliases & Classifications for Macroglobulinemia

MalaCards integrated aliases for Macroglobulinemia:

Name: Macroglobulinemia 12 72 14
Waldenstrom Macroglobulinemia 69
Primary Macroglobulinemia 12

Classifications:



Summaries for Macroglobulinemia

MalaCards based summary : Macroglobulinemia, also known as waldenstrom macroglobulinemia, is related to waldenstrom macroglobulinemia and lymphoplasmacytic lymphoma. An important gene associated with Macroglobulinemia is MYD88 (Myeloid Differentiation Primary Response 88), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Dexamethasone and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 72 Macroglobulinemia is the presence of increased levels of macroglobulins in the circulating blood. It is... more...

Related Diseases for Macroglobulinemia

Diseases related to Macroglobulinemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 200)
# Related Disease Score Top Affiliating Genes
1 waldenstrom macroglobulinemia 33.1 CD40LG CXCR4 IL6 MYD88 PAX5 TNFSF13B
2 lymphoplasmacytic lymphoma 31.7 CD40LG CXCL12 CXCR4 MYD88 PAX5
3 cryoglobulinemia 30.1 CD27 CD40LG TNFSF13B
4 heavy chain disease 30.0 CD40LG MYD88
5 whim syndrome 29.6 CXCL12 CXCR4
6 myeloma, multiple 29.5 AKT1 CD40LG CXCR4 IL6 TNFSF13B
7 agammaglobulinemia 29.4 BTK CD40LG CXCL12
8 mantle cell lymphoma 29.3 AKT1 BTK CD40LG
9 hematologic cancer 29.3 CXCL12 CXCR4 PAX5
10 autoimmune disease 28.9 CD40LG IL6 TNFRSF13B TNFSF13B
11 lymphoma, non-hodgkin, familial 28.0 CD27 CD40LG CXCL12 CXCR4 PAX5 TNFRSF13B
12 leukemia, chronic lymphocytic 27.7 CD27 CD40LG CD70 CXCL12 CXCR4 PAX5
13 macroglobulinemia, waldenstrom 1 12.2
14 waldenstroem's macroglobulinemia 12.0
15 macroglobulinemia, waldenstrom 2 12.0
16 schnitzler syndrome 11.4
17 monoclonal gammopathy of uncertain significance 11.2
18 light chain deposition disease 11.2
19 lymphoma 10.5
20 immunodeficiency with hyper-igm, type 4 10.4 CD40LG TNFSF13B
21 immunoglobulin a deficiency 1 10.4 BTK CD40LG
22 selective immunoglobulin deficiency disease 10.4 BTK CD40LG
23 polyclonal hypergammaglobulinemia 10.4 CD40LG IL6
24 congenital hypogammaglobulinemia 10.4 BTK CD40LG
25 ascaris lumbricoides infection 10.3 IL6 TNFSF13B
26 immunodeficiency with hyper-igm, type 1 10.3 BTK CD40LG
27 transient arthritis 10.3 CD40LG IL6
28 toxoplasmosis 10.3 CD40LG IL6 MYD88
29 aids dementia complex 10.3 CXCL12 CXCR4
30 central nervous system vasculitis 10.2 CD40LG IL6
31 hypersensitivity reaction disease 10.2 CD40LG IL6 TNFSF13B
32 immune system disease 10.2 CD40LG IL6 TNFSF13B
33 viral infectious disease 10.2 CD40LG CXCR4 IL6
34 osteosclerotic myeloma 10.2 CD40LG IL6
35 leukemia 10.2
36 connective tissue disease 10.2 CD40LG IL6 TNFSF13B
37 non-secretory myeloma 10.1 CD40LG ITGAE
38 monoclonal paraproteinemia 10.1 CD27 CD40LG MYD88
39 primary central nervous system lymphoma 10.1 CXCL12 MYD88 PAX5
40 intraocular lymphoma 10.1 CXCL12 CXCR4 PAX5
41 b-cell lymphomas 10.1
42 amyloidosis 10.1
43 plasma protein metabolism disease 10.1 BTK CD40LG CXCR4 MYD88
44 intussusception 10.1 CD40LG IL6
45 immunoglobulin alpha deficiency 10.1 CD40LG TNFRSF13B
46 lymph node disease 10.1 CD40LG IL6 ITGAE
47 neuropathy 10.0
48 lymphoproliferative syndrome 2 10.0 CD27 CD40LG CD70
49 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.0
50 diffuse large b-cell lymphoma 10.0

Graphical network of the top 20 diseases related to Macroglobulinemia:



Diseases related to Macroglobulinemia

Symptoms & Phenotypes for Macroglobulinemia

GenomeRNAi Phenotypes related to Macroglobulinemia according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 AKT1 CD40LG CD70 CXCR4 MYD88
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 AKT1 BTK CD27 CD40LG CD70 CXCR4

MGI Mouse Phenotypes related to Macroglobulinemia:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.97 AKT1 BTK CD27 CD40LG CD70 CXCL12
2 cellular MP:0005384 9.91 AKT1 BTK CD27 CD40LG CXCL12 CXCR4
3 immune system MP:0005387 9.77 CD40LG CD70 CXCL12 CXCR4 IL6 ITGAE
4 neoplasm MP:0002006 9.17 AKT1 BTK CXCR4 IL6 MYD88 PAX5

Drugs & Therapeutics for Macroglobulinemia

Drugs for Macroglobulinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 374)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
2
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 33419-42-0 36462
3
Cytarabine Approved, Investigational Phase 4,Phase 2,Phase 1 147-94-4 6253
4
Methotrexate Approved Phase 4,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
5
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
6
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
7
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 179324-69-7 387447 93860
8 Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3 52-24-4 5453
9
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
10
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 1 50-24-8 5755
11
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 1 83-43-2 6741
12
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
13
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 1,Early Phase 1 58-05-9 143 6006
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
15 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1 1177-87-3
16 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1
19 Folic Acid Antagonists Phase 4,Phase 2,Phase 1,Early Phase 1
20 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
21 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
22 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 1,Early Phase 1
23 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Vitamin B Complex Phase 4,Phase 2,Phase 1,Early Phase 1
26 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
31 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Immunoglobulins Phase 4,Phase 2,Phase 1,Early Phase 1
33 Etoposide phosphate Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
34 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1
35 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
37 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
39 Protective Agents Phase 4,Phase 2,Phase 1
40 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Antibodies Phase 4,Phase 2,Phase 1,Early Phase 1
42 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1
43 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Prednisolone acetate Phase 4,Phase 2,Phase 1
46 Methylprednisolone acetate Phase 4,Phase 2,Phase 1
47 Methylprednisolone Hemisuccinate Phase 4,Phase 2,Phase 1
48 Neuroprotective Agents Phase 4,Phase 2,Phase 1
49 Angiogenesis Inhibitors Phase 4,Phase 1,Phase 2
50 Angiogenesis Modulating Agents Phase 4,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 469)

# Name Status NCT ID Phase Drugs
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia Recruiting NCT02844322 Phase 4 Bortezomib;Rituximab
3 Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia Recruiting NCT02844361 Phase 4
4 The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM Recruiting NCT02844309 Phase 4 Thalidomide
5 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
6 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
7 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
8 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
9 Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia Completed NCT00566332 Phase 3 Chlorambucil;Fludarabine
10 Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma Completed NCT00608374 Phase 3 chlorambucil;fludarabine phosphate
11 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
12 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
13 Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation Completed NCT00031668 Phase 3
14 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
15 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
16 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
17 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
18 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
19 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
20 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
21 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
22 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
23 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
24 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
25 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
26 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
27 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
28 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. Completed NCT00801281 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2
29 A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM) Recruiting NCT03053440 Phase 3 BGB-3111;Ibrutinib
30 Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia Recruiting NCT01788020 Phase 3 Dexamethasone, Rituximab, Cyclophosphamide;Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
31 Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Recruiting NCT02991638 Phase 3 Ibrutinib
32 Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia Active, not recruiting NCT02165397 Phase 3 Ibrutinib;Placebo;Rituximab
33 A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneo Active, not recruiting NCT01461928 Phase 3 Chemotherapy (Induction Period);Rituximab
34 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
35 Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated NCT01732926 Phase 3 Idelalisib;Rituximab;Bendamustine;Placebo
36 Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated NCT01732913 Phase 3 Placebo;Rituximab;Idelalisib
37 A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia Unknown status NCT01142011 Phase 2 Belimumab
38 Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia Unknown status NCT01046006 Phase 2 Bortezomib, Rituximab, Dexamethasone
39 Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia Unknown status NCT00041379 Phase 1, Phase 2 beta alethine
40 A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 Unknown status NCT01813227 Phase 2 Carfilzomib;Rituximab;Dexamethasone
41 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
42 Comparison of Fludarabine Plus Total-Body Irradiation With Combination Chemotherapy Followed by Donor Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Unknown status NCT00041288 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;methotrexate;mycophenolate mofetil;tacrolimus
43 Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma Unknown status NCT00937183 Phase 1, Phase 2
44 Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers Unknown status NCT00003163 Phase 2 cyclophosphamide;melphalan
45 Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma Unknown status NCT00397800 Phase 1, Phase 2 cyclophosphamide;fludarabine phosphate
46 Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma Unknown status NCT00474929 Phase 1, Phase 2 RAD001;Sorafenib
47 Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia Unknown status NCT01016990 Phase 2 valproic acid
48 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2 methotrexate;thiotepa
49 Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia Completed NCT02092909 Phase 1, Phase 2 IMO-8400
50 Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia Completed NCT02302469 Phase 1, Phase 2 Revlimid

Search NIH Clinical Center for Macroglobulinemia

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Macroglobulinemia

Anatomical Context for Macroglobulinemia

MalaCards organs/tissues related to Macroglobulinemia:

38
B Cells, Bone, Bone Marrow, Liver, T Cells, Kidney, Spleen

Publications for Macroglobulinemia

Articles related to Macroglobulinemia:

(show top 50) (show all 822)
# Title Authors Year
1
Fitting mSMART Into the Current Clinical Management of WaldenstrAPm Macroglobulinemia-Reply. ( 29392293 )
2018
2
Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's macroglobulinemia. ( 29218718 )
2018
3
A rare neurological complication of Waldenstrom's Macroglobulinemia. ( 29113857 )
2018
4
Fitting mSMART Into the Current Clinical Management of WaldenstrAPm Macroglobulinemia. ( 29392274 )
2018
5
Intensely Pruritic Papules and Plaques in Waldenstrom's Macroglobulinemia. ( 29386839 )
2018
6
Waldenstrom's Macroglobulinemia: An Update. ( 29326801 )
2018
7
Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for WaldenstrAPm Macroglobulinemia. ( 29439186 )
2018
8
MYD88 mutation status does not impact overall survival in WaldenstrAPm macroglobulinemia. ( 29080258 )
2018
9
Calorimetric markers for monitoring of multiple myeloma and WaldenstrAPm's macroglobulinemia patients. ( 29362827 )
2018
10
Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series. ( 28583038 )
2018
11
Diagnostic Tools of WaldenstrAPms Macroglobulinemia - Best Possibilities for Non-invasive and Long-term Disease Monitoring. ( 28903575 )
2017
12
Dexamethasone, rituximab and cyclophosphamide for relapsedA and/or refractory and treatment-naA^ve patients with Waldenstrom macroglobulinemia. ( 28786474 )
2017
13
A case of Waldenstrom Macroglobulinemia in which intermittent one-day administration cycles of bendamustine were effective for alleviation of nausea and maintenance of remission. ( 28883220 )
2017
14
Current options to manage WaldenstrAPm's macroglobulinemia. ( 28592170 )
2017
15
Acquired mutations associated with ibrutinib resistance in WaldenstrAPm macroglobulinemia. ( 28235842 )
2017
16
Primary SjAPgren's syndrome with WaldenstrAPm's macroglobulinemia presenting as unilateral bloody pleural effusion. ( 28705308 )
2017
17
Waldenstrom macroglobulinemia presenting as a bilateral subdural chronic hematoma. ( 28262409 )
2017
18
Significances of MYD88(L265P) and CXCR4(WHIM) Mutations in Waldenstrom Macroglobulinemia. ( 28877839 )
2017
19
Case 244: Systemic Amyloidosis-A Complication of WaldenstrAPm Macroglobulinemia. ( 28723285 )
2017
20
WaldenstrAPm Macroglobulinemia: Review of Pathogenesis and Management. ( 28366781 )
2017
21
Genomics, Signaling, and Treatment of WaldenstrAPm Macroglobulinemia. ( 28294689 )
2017
22
Novel approaches to targeting MYD88 in WaldenstrAPm macroglobulinemia. ( 28617062 )
2017
23
Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. ( 28548645 )
2017
24
New developments in the management of WaldenstrAPm macroglobulinemia. ( 28331368 )
2017
25
Pattern of somatic mutations in patients with WaldenstrAPm macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. ( 28983055 )
2017
26
Waldenstrom's Macroglobulinemia: A Report of Two Cases, One with Severe Retinopathy and One with Renal Failure. ( 29225979 )
2017
27
Localized retinal degeneration secondary to WaldenstrAPm's macroglobulinemia. ( 29118506 )
2017
28
The Diagnostic, Prognostic, and Therapeutic Utility of Molecular Testing in a Patient with Waldenstrom's Macroglobulinemia. ( 28937595 )
2017
29
Role of IRF4 in resistance to immunomodulatory (IMid) compounds<sup>Ar</sup>in WaldenstrAPm's macroglobulinemia. ( 29348877 )
2017
30
Low-dose bortezomib and dexamethasone as primary therapy in elderly patients with WaldenstrOsm macroglobulinemia. ( 28801984 )
2017
31
Diagnosis and Management of WaldenstrAPm Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. ( 28056114 )
2017
32
Cutaneous Infiltration due to WaldenstrAPm Macroglobulinemia. ( 28784233 )
2017
33
Normothermic Cardiopulmonary Bypass in Patient With WaldenstrAPm's Macroglobulinemia and Cryoglobulinemia: A Case Report. ( 28520564 )
2017
34
Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia. ( 28043164 )
2017
35
Systemic Amyloidosis and Cardiac Autonomic Neuropathy Associated with Waldenstrom's Macroglobulinemia. ( 28695027 )
2017
36
A phase II Bayesian sequential clinical trial in advanced WaldenstrAPm macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone. ( 28395585 )
2017
37
Ibrutinib discontinuation in WaldenstrAPm macroglobulinemia: Etiologies, outcomes, and IgM rebound. ( 29280186 )
2017
38
Utility of MYD88 in the Differential Diagnosis and Choice of Second-Line Therapy in a Case of Nonsecretory Lymphoplasmacytic Lymphoma versus Free Light Chain Waldenstrom's Macroglobulinemia. ( 28286680 )
2017
39
Toward personalized treatment in WaldenstrAPm macroglobulinemia. ( 29222280 )
2017
40
From WaldenstrAPm's macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation. ( 28841204 )
2017
41
Allogeneic Transplantation for Relapsed WaldenstrAPm Macroglobulinemia and Lymphoplasmacytic Lymphoma. ( 27789362 )
2017
42
Rare transformation to double hit lymphoma in Waldenstrom's macroglobulinemia. ( 28771100 )
2017
43
MYD88 L265P mutation in cutaneous involvement by WaldenstrAPm macroglobulinemia. ( 28370087 )
2017
44
EDTA-induced pseudothrombocytosis and citrate-induced platelet agglutination in a patient with Waldenstrom macroglobulinemia. ( 28781833 )
2017
45
TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia. ( 28754818 )
2017
46
Monoclonal IgM Gammopathy and WaldenstrAPm's Macroglobulinemia. ( 29169431 )
2017
47
WaldenstrAPm macroglobulinemia: 2017 update on diagnosis, risk stratification, and management. ( 28094456 )
2017
48
Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom's macroglobulinemia. ( 29203585 )
2017
49
A Case of Waldenstrom Macroglobulinemia with Temporary Appearance of 7S IgM Half Molecule. ( 28627827 )
2017
50
Cost-effectiveness analysis of ibrutinib in patients with WaldenstrAPm macroglobulinemia in Italy. ( 29201288 )
2017

Variations for Macroglobulinemia

Expression for Macroglobulinemia

Search GEO for disease gene expression data for Macroglobulinemia.

Pathways for Macroglobulinemia

Pathways related to Macroglobulinemia according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.89 AKT1 BTK CD27 CD40LG CD70 IL6
2
Show member pathways
13.69 AKT1 BTK CD27 CD40LG CD70 CXCL12
3
Show member pathways
13.55 AKT1 BTK CD27 CD40LG CD70 CXCL12
4
Show member pathways
13.41 AKT1 BTK CXCL12 CXCR4 IL6 ITGAE
5
Show member pathways
13.25 AKT1 CD27 CD40LG CD70 IL6 MYD88
6
Show member pathways
13.02 AKT1 BTK CD27 CD40LG CD70 CXCL12
7
Show member pathways
12.92 AKT1 BTK CXCL12 IL6 ITGAE
8
Show member pathways
12.77 CD40LG CXCL12 CXCR4 IL6 TNFRSF13B TNFSF13B
9
Show member pathways
12.62 AKT1 CD40LG CXCL12 IL6 MYD88 TNFSF13B
10
Show member pathways
12.58 AKT1 CD27 CD40LG CD70 CXCR4
11
Show member pathways
12.55 AKT1 BTK CD27 CD40LG CD70 CXCL12
12 12.43 BTK CD40LG CXCL12 CXCR4 MYD88 PAX5
13
Show member pathways
12.29 AKT1 BTK CD27 CD40LG CD70 MYD88
14 11.83 BTK CD40LG CXCL12 MYD88 TNFSF13B
15 11.78 AKT1 CXCL12 CXCR4 IL6
16 11.75 CXCL12 IL6 TNFSF13B
17
Show member pathways
11.74 CD27 CD40LG CD70 TNFRSF13B TNFSF13B
18 11.67 AKT1 CXCL12 CXCR4
19
Show member pathways
11.65 CD40LG TNFRSF13B TNFSF13B
20 11.59 AKT1 CXCL12 CXCR4
21 11.54 CD27 CD40LG CD70
22 11.46 CD40LG IL6 MYD88
23 11.44 CD27 CD40LG CXCR4 PAX5 TNFRSF13B
24 11.32 BTK CD40LG TNFRSF13B
25 11.25 CD40LG IL6 ITGAE PAX5 TNFRSF13B TNFSF13B
26 11.23 CXCL12 CXCR4 TNFRSF13B
27 11.11 BTK CD40LG CD70 CXCL12 IL6 TNFSF13B
28 10.94 BTK CD40LG CD70 CXCL12 IL6 ITGAE

GO Terms for Macroglobulinemia

Cellular components related to Macroglobulinemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.4 AKT1 BTK CD27 CD40LG CD70 CXCL12
2 external side of plasma membrane GO:0009897 9.26 CD27 CD40LG CXCL12 ITGAE

Biological processes related to Macroglobulinemia according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.93 AKT1 BTK CD27 CXCR4 MYD88
2 negative regulation of apoptotic process GO:0043066 9.88 AKT1 CD27 CD40LG IL6 MYD88
3 regulation of receptor activity GO:0010469 9.77 CD40LG CD70 CXCL12 IL6 TNFSF13B
4 platelet activation GO:0030168 9.73 AKT1 CD40LG IL6
5 response to virus GO:0009615 9.72 CXCL12 CXCR4 MYD88
6 T cell costimulation GO:0031295 9.67 AKT1 CD40LG TNFSF13B
7 immune response GO:0006955 9.63 CD27 CD40LG CD70 CXCL12 IL6 TNFSF13B
8 positive regulation of T cell proliferation GO:0042102 9.61 CD40LG IL6 TNFSF13B
9 endocrine pancreas development GO:0031018 9.58 AKT1 IL6
10 B cell homeostasis GO:0001782 9.58 TNFRSF13B TNFSF13B
11 positive regulation of smooth muscle cell proliferation GO:0048661 9.58 AKT1 IL6 MYD88
12 negative regulation of B cell proliferation GO:0030889 9.57 BTK TNFRSF13B
13 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.56 BTK CD40LG IL6 MYD88
14 positive regulation of B cell differentiation GO:0045579 9.52 BTK CD27
15 immunoglobulin mediated immune response GO:0016064 9.51 CD27 MYD88
16 response to peptidoglycan GO:0032494 9.46 IL6 MYD88
17 inflammatory response GO:0006954 9.43 AKT1 CD27 CD40LG CXCR4 IL6 MYD88
18 immunoglobulin secretion GO:0048305 9.32 CD40LG TNFSF13B
19 tumor necrosis factor-mediated signaling pathway GO:0033209 9.02 CD27 CD40LG CD70 TNFRSF13B TNFSF13B

Molecular functions related to Macroglobulinemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor binding GO:0005102 9.55 BTK CD70 CXCL12 MYD88 TNFSF13B
2 tumor necrosis factor receptor binding GO:0005164 9.13 CD40LG CD70 TNFSF13B
3 cytokine activity GO:0005125 9.02 CD40LG CD70 CXCL12 IL6 TNFSF13B

Sources for Macroglobulinemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....